Cytochroma is a clinical stage specialty pharmaceutical company focused on developing and commercializsng proprietary products to treat and prevent the clinical consequences of Vitamin D insufficiency and SHPT associated with CKD.
The company's Vitamin D-based therapeutics are designed to safely and effectively treat pre-dialysis and dialysis CKD patients. In addition, Cytochroma is developing novel therapies to treat hyperphosphatemia.
Cytochroma has opened the compan’s US headquarters in Bannockburn, Illinois, located in the greater Chicago area at a site that will serve as the company's base for US commercial activities and for the expansion of its North American clinical and regulatory operations.
